Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.13% is 69% below its 3-year average of 0.44%, near the low end of its 3-year range (0.13%–0.72%).
As of the fiscal period ended Tuesday, June 30, 2026. 47.84% below its 12-month average of 0.26%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.13%.
DEBT TO ASSETS RATIO
0.13%
DEBT TO ASSETS RATIO AVG TTM
0.26%
DEBT TO ASSETS RATIO AVG 3Y
0.44%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-47.84%
CURRENT VS 3Y AVG
-69.47%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+33.02%
vs the sector median at left
Jade Biosciences, Inc.
Market Cap
$820.39M
Debt to Assets Ratio
0.13%
TTM Avg
0.26%
3Y Avg
0.44%
5Y Avg
N/A
Market Cap
$835.01M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$843.53M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$791.01M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $820.39M | 0.13% | 0.26% | 0.44% | N/A |
| Apnimed, Inc. (APMD)vs › | $818.83M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $825.62M | 0.06% | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $809.02M | 0.44% | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $808.81M | 0.01% | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $835.01M | 0.02% | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $793.88M | 0.48% | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $843.53M | 0.05% | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $791.01M | 0.02% | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $865.29M | 0.00% | N/A | N/A | N/A |
Debt/Assets
0.1%
Debt/Equity
0.00
Current Ratio
14.93
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.13% |
| 2026-03-31 | 0.21% |
| 2025-12-31 | 0.21% |
| 2025-09-30 | 0.37% |
| 2025-06-30 | 0.35% |
| 2025-03-31 | 0.40% |
| 2024-12-31 | 0.52% |
| 2024-09-30 | 0.59% |
| 2024-06-30 | 0.61% |
| 2024-03-31 | 0.72% |
| 2023-12-31 | 0.53% |
| 2023-09-30 | 0.57% |
